---
title: "Social Determinants of Health and GLP-1 RA Use in Type 2 Diabetes with Stage 2 CKM: NHANES 2005–20"
id: "medrxiv-23-social-determinants-of-health-and-glp-1-ra-use-among-patients-with-type-2"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-23-social-determinants-of-health-and-glp-1-ra-use-among-patients-with-type-2"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.18.26360763v1?rss=1"
published_at: "2026-08-21T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Social Determinants of Health and GLP-1 RA Use in Type 2 Diabetes with Stage 2 CKM: NHANES 2005–20
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-23-social-determinants-of-health-and-glp-1-ra-use-among-patients-with-type-2
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.18.26360763v1?rss=1)
- **Published At:** 2026-08-21T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This cross-sectional analysis used NHANES 2005–2020 to examine how **social determinants of health (SDoH)** influence use of **GLP-1 receptor agonists (GLP-1 RA)** among adults aged ≥30 years with type 2 diabetes (T2D) and/or other stage 2 cardiovascular-kidney-metabolic (CKM) conditions. - The analytic sample comprised 4,520 participants, representing approximately 84.0 million U.S. adults; weighted mean age was 61.4 years, 48.9% female, and 61.5% non-Hispanic White. - Use of **GLP-1 RA** differed across SDoH strata: higher education (3.39% vs 1.43%), private insurance (3.00% vs 0.58%), and higher income (4.70% vs 1.87%) had greater GLP-1 RA use; no GLP-1 RA use was observed among those without a routine place for care. - In multivariable adjusted models, lower income, less than high school education, lack of insurance, and being unmarried were associated with 64%, 51%, 81%, and 40% lower likelihoods of GLP-1 RA use, respectively (as reported in the source). - LASSO variable selection identified income, education, insurance status, and access to care as key predictors of GLP-1 RA use in this population. - Additional adjusted analyses accounting for age, sex, and race/ethnicity found lower income, lower educational attainment, and lack of insurance associated with 48%, 34%, and 79% lower likelihoods of GLP-1 RA use, respectively. - Authors conclude that SDoH-related disparities limit access to GLP-1 RA; addressing socioeconomic barriers is important to slow CKM progression, reduce cardiovascular risk, and mitigate health disparities. - The study used publicly available, de-identified NHANES data and is a preprint; it has not been peer reviewed and should not be used alone to change clinical practice.
## Clinical Analysis & Structured Key Points
Social Determinants of Health and GLP-1 RA Use Among Patients with Type 2 Diabetes and Stage 2 CKM: Insights from NHANES 2005?2020 | medRxiv Skip to main content Social Determinants of Health and GLP-1 RA Use Among Patients with Type 2 Diabetes and Stage 2 CKM: Insights from NHANES 2005?2020 View ORCID Profile Qi Jian , Mark S. Segal , Hui Shao , Naikky Singh-Ospina , View ORCID Profile Tianze Jiao doi: https://doi.org/10.64898/2026.08.18.26360763 Qi Jian 1 University of Florida College of Pharmacy, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Qi Jian Mark S. Segal 2 University of Florida College of Medicine, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hui Shao 3 Emory University, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Naikky Singh-Ospina 4 Division of Endocrinology, Department of Medicine, University of Florida, Gainesville, FL Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tianze Jiao 1 University of Florida College of Pharmacy, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Tianze Jiao For correspondence: tianzejiao{at}ufl.edu Abstract Info/History Metrics Data/Code Preview PDF Abstract Background Cardiovascular-Kidney-Metabolic (CKM) syndrome encompasses interconnected conditions such as type 2 diabetes (T2D), hypertension, hypertriglyceridemia, metabolic syndrome (MetS), and chronic kidney disease (CKD). As CKM progresses, cardiorenal risks increase. Although Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have demonstrated cardiorenal and cardiometabolic benefits, offering an opportunity to slow CKM progression, their use may vary across social determinants of health (SDoH) and stage 2 CKM subgroups. Objective To evaluate the influence of SDoH on access to GLP-1 RA among patients with T2D and other stage 2 CKM conditions. Methods This cross-sectional study used data from the U.S. National Health and Nutrition Examination Survey (NHANES), 2005?2020. Adults aged ≥30 years with T2D and/or other stage 2 CKM conditions were included. Weighted descriptive analysis, multivariable logistic regression and LASSO were applied to assess associations between SDoH and GLP-1 RA use. Results Among 4,520 participants (representing approximately 84.0 million U.S. adults), weighted mean age was 61.4 years, 48.9% were female, and 61.5% were non-Hispanic White. Among participants with T2D, GLP-1 RA use was higher among individuals with higher education (3.39% vs 1.43%), private insurance (3.00% vs 0.58%), and higher income (4.70% vs 1.87%), while no use was observed among those without routine places for care. In adjusted analyses, individuals with lower income, less than high school education, lack of insurance, and being unmarried had 64%, 51%, 81%, and 40% lower likelihood of GLP-1 RA use, respectively. LASSO identified income, education, insurance, and access to care as predictors. Lower income, lower educational attainment, and lack of insurance were associated with 48%, 34%, and 79% lower likelihood of GLP-1 RA use, respectively, adjusting for age, sex, and race/ethnicity. Conclusion SDoH-driven disparities limit GLP-1 RA access. Expanding GLP-1 RA access by addressing socioeconomic barriers is critical to slowing CKM progression, reducing cardiovascular risk, and mitigating health disparities. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The NHANES protocol was approved by the National Center for Health Statistics (NCHS) Research Ethics Review Board, and written informed consent was obtained from all participants. The present study used publicly available, de-identified data and was therefore considered exempt from University of Florida institutional review board review. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The National Health and Nutrition Examination Survey (NHANES) data files and survey documentation used in this study are publicly available and can be accessed through the NHANES website at https://wwwn.cdc.gov/nchs/nhanes/. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Posted August 21, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Social Determinants of Health and GLP-1 RA Use Among Patients with Type 2 Diabetes and Stage 2 CKM: Insights from NHANES 2005?2020 Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Social Determinants of Health and GLP-1 RA Use Among Patients with Type 2 Diabetes and Stage 2 CKM: Insights from NHANES 2005?2020 Qi Jian , Mark S. Segal , Hui Shao , Naikky Singh-Ospina , Tianze Jiao medRxiv 2026.08.18.26360763; doi: https://doi.org/10.64898/2026.08.18.26360763 Share This Article: Copy Citation Tools Social Determinants of Health and GLP-1 RA Use Among Patients with Type 2 Diabetes and Stage 2 CKM: Insights from NHANES 2005?2020 Qi Jian , Mark S. Segal , Hui Shao , Naikky Singh-Ospina , Tianze Jiao medRxiv 2026.08.18.26360763; doi: https://doi.org/10.64898/2026.08.18.26360763 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (607) Allergy and Immunology (891) Anesthesia (324) Cardiovascular Medicine (4735) Dentistry and Oral Medicine (473) Dermatology (404) Emergency Medicine (637) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1606) Epidemiology (15761) Forensic Medicine (32) Gastroenterology (1193) Genetic and Genomic Medicine (6942) Geriatric Medicine (723) Health Economics (1048) Health Informatics (4936) Health Policy (1417) Health Systems and Quality Improvement (1728) Hematology (574) HIV/AIDS (1322) Infectious Diseases (except HIV/AIDS) (16215) Intensive Care and Critical Care Medicine (1155) Medical Education (657) Medical Ethics (150) Nephrology (714) Neurology (7126) Nursing (359) Nutrition (1066) Obstetrics and Gynecology (1217) Occupational and Environmental Health (992) Oncology (3557) Ophthalmology (1030) Orthopedics (387) Otolaryngology (442) Pain Medicine (463) Palliative Medicine (138) Pathology (702) Pediatrics (1764) Pharmacology and Therapeutics (729) Primary Care Research (754) Psychiatry and Clinical Psychology (5790) Public and Global Health (9637) Radiology and Imaging (2364) Rehabilitation Medicine and Physical Therapy (1418) Respiratory Medicine (1234) Rheumatology (631) Sexual and Reproductive Health (761) Sports Medicine (571) Surgery (756) Toxicology (106) Transplantation (300) Urology (285)
## Related Clinical Research

- [Adherence to Medications, Lifestyle Advice, and Self‑Monitoring for Type 2 Diabetes and Hypertensi](https://medichelpline.com/clinical-feed/plos-medicine-0-adherence-to-medications-lifestyle-advice-and-self-monitoring-for-type-2.md)
- [Quality of Type 2 Diabetes Care in Malaysian Primary Care: ABC (HbA1c, BP, LDL-C) Scoping Review](https://medichelpline.com/clinical-feed/plos-one-3-the-quality-of-care-for-type-2-diabetes-mellitus-management-in-malaysian.md)
- [Single-cell scTWAS identifies immune cell–specific genes linked to gestational diabetes](https://medichelpline.com/clinical-feed/plos-one-0-leveraging-expression-quantitative-trait-loci-information-in-single-cell.md)
- [Moving Forward: The Future of GLP-1 Therapies](https://medichelpline.com/clinical-feed/endocrine-news-18-moving-forward-the-future-of-glp-1-therapies.md)
- [Pilomatricoma Presenting in an Octogenarian: Rare Late-Life Scalp Tumor Case Report](https://medichelpline.com/clinical-feed/pubmed-42638289.md) (DOI: 10.12659/AJCR.953320)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.